CONTEXT: Apelin is an adipokine expressed in several tissues and it appears to be involved in energy metabolism. OBJECTIVE: The aim of this study was to determine serum apelin levels in a large cohort of patients with type 1 and type 2 diabetes and control subjects and to correlate the results with glycaemic control. DESIGN AND PARTICIPANTS: One hundred and thirty patients with type 1 diabetes, 98 patients with type 2 diabetes and 162 controls were enrolled in the study. Apelin levels were measured by enzyme-linked immunosorbent assay. RESULTS: Serum apelin levels were significantly higher in type 1 and type 2 diabetic patients than in controls (P < 0·0001). Serum apelin levels were higher in type 1 than in type 2 diabetic patients (P = 0·02). In multivariate analysis, serum apelin levels were higher in patients with type 1 diabetes and in patients with type 2 diabetes versus controls. We found a negative correlation between glycosylated haemoglobin and serum apelin levels in all diabetic patients (r = -0·17, P = 0·008) and in patients with type 2 diabetes (r = -0·24 P = 0·01). No correlation was found in type 1 diabetic patients. CONCLUSION: Our study showed that apelin concentrations were increased in diabetic patients. This rise, which was greater in type 1 than in type 2 diabetic patients, suggests that obesity is not the main determinant of plasma apelin levels. The negative correlation with glycosylated haemoglobin in patients with type 2 diabetes could indicate that apelin plays a role in glycaemic balance and even insulin sensitivity.
CONTEXT: Apelin is an adipokine expressed in several tissues and it appears to be involved in energy metabolism. OBJECTIVE: The aim of this study was to determine serum apelin levels in a large cohort of patients with type 1 and type 2 diabetes and control subjects and to correlate the results with glycaemic control. DESIGN AND PARTICIPANTS: One hundred and thirty patients with type 1 diabetes, 98 patients with type 2 diabetes and 162 controls were enrolled in the study. Apelin levels were measured by enzyme-linked immunosorbent assay. RESULTS: Serum apelin levels were significantly higher in type 1 and type 2 diabeticpatients than in controls (P < 0·0001). Serum apelin levels were higher in type 1 than in type 2 diabeticpatients (P = 0·02). In multivariate analysis, serum apelin levels were higher in patients with type 1 diabetes and in patients with type 2 diabetes versus controls. We found a negative correlation between glycosylated haemoglobin and serum apelin levels in all diabeticpatients (r = -0·17, P = 0·008) and in patients with type 2 diabetes (r = -0·24 P = 0·01). No correlation was found in type 1 diabeticpatients. CONCLUSION: Our study showed that apelin concentrations were increased in diabeticpatients. This rise, which was greater in type 1 than in type 2 diabeticpatients, suggests that obesity is not the main determinant of plasma apelin levels. The negative correlation with glycosylated haemoglobin in patients with type 2 diabetes could indicate that apelin plays a role in glycaemic balance and even insulin sensitivity.
Authors: C Santangelo; C Filesi; R Varì; B Scazzocchio; T Filardi; V Fogliano; M D'Archivio; C Giovannini; A Lenzi; S Morano; R Masella Journal: J Endocrinol Invest Date: 2016-06-25 Impact factor: 4.256
Authors: Soha M Abd El Dayem; Ahmed A Battah; Abo El Maged El Bohy; Rash Nazih Yousef; Azza M Ahmed; Ahmed A Talaat Journal: Open Access Maced J Med Sci Date: 2017-12-04
Authors: Rania N Sabry; Maged A El Wakeel; Ghada M El-Kassas; Ahmed F Amer; Wael H El Batal; Salwa Refat El-Zayat; Mohamed Abou-El-Asrar Journal: Open Access Maced J Med Sci Date: 2018-04-04
Authors: Moriah P Bellissimo; Emory Hsu; Li Hao; Kirk Easley; Greg S Martin; Thomas R Ziegler; Jessica A Alvarez Journal: J Clin Transl Endocrinol Date: 2021-06-06